Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Bifeprunox in Schizophrenia or Schizoaffective Disorder
NCT00347425Phase 3Completed
- Sponsor
- Solvay
- Start
- Dec 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of bifeprunox in schizophrenia, schizoaffective disorder, sponsored by Solvay. Started Dec 2006; status: completed.
02
Drugs
bifeprunox
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00347425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00347425.